Characterization of NCI60 and Melanoma Cell Lines

LOX IMVI, M14, MDA-MB-435, SK-MEL-28, and UACC-257 are part of the NCI60 cancer cell line established by the National Cancer Institute (Bethesda, MD, USA) for drug testing (reviewed in [11 (link)]) and were purchased from NCI-Frederick Cancer Center DCTD Tumor/Cell Repository. Melanoma cell lines A375, M26, M19, and FM-88 were contributed by the Department of Dermatology, University Hospital Würzburg, Germany, as reported previously [12 (link)]. Six melanoma cell lines (MEL-JUSO, IGR-1, IGR-37, IGR-39, SK-MEL-3, SK-MEL-30) were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ), Braunschweig, Germany, while AXBI, LIWE-7, ARST-1, ICNI-5li, and UMBY-1 were contributed by the Department of Dermatology, University Hospital Erlangen, Germany, as reported previously [13 (link)]. All cells were propagated in DMEM supplemented with 10% heat-inactivated (56 °C, 60 min) fetal calf serum, 90 U/mL streptomycin, 0.3 mg/mL glutamine, and 200 U/mL penicillin (all Pan Biotech, Aidenbach, Germany). All cell lines were tested regularly for mycoplasma using PCR.